Menu
 

Search abstracts


Affordability of risperidone and aripiprazole for the treatment of autism spectrum disorder

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: SADAF, Shaista (University of Malta, Department of Pharmacy)
  • Co-author(s): Shaista Sadaf: Department of Pharmacy, University of Malta, Msida, Malta
    Maresca Attard Pizzuto: Department of Pharmacy, University of Malta, Msida, Malta
    Luana Mifsud Buhagiar: Department of Pharmacy, University of Malta, Msida, Malta
    Maurice Zarb Adami: Department of Pharmacy, University of Malta, Msida, Malta
    Anthony Serracino Inglott: Department of Pharmacy, University of Malta, Msida, Malta
  • Abstract:

    Background

    The use of risperidone and aripiprazole in children and adolescents with Autism Spectrum Disorder (ASD) is off-label in India and Malta and is not included in the national formularies. The European Medicines Agency and the Central Drug Standard Control Organisation (India) have not approved the drug for the indication of ASD.

    Methods

    A

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses